Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome

International Journal of Tuberculosis and Lung Disease

Volumn 2, Issue 6, 1998, Pages 462-470

  Roussel, Guy ^a,b   Igual, J ^a  

^a Hopital Laennec   (France)

^b NONE   (France)

Author keywords

Clarithromycin; HIV seronegative; Mycobacterium avium intracellulare infection

Indexed keywords

AMIKACIN; CLARITHROMYCIN; CLOFAZIMINE; MINOCYCLINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; OTOTOXICITY; PRIORITY JOURNAL;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; CLOFAZIMINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV SERONEGATIVITY; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 0031844294     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Snider D E, Hopewell P C, Mills J, Reichman L B. Mycobacterioses and the acquired immunodeficiency syndrome. Am Rev Respir Dis 1987; 136: 492-498.
2. Prince D S, Peterson D D. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 1989; 321: 863-868.
3. Iseman M D. Mycobacterium avium complex and the normal host. N Engl J Med 1989; 321: 896-898.
4. Heifets L B, Iseman M D. Individualized therapy versus standard regimens in the treatment of Mycobacterium avium infections. Am Rev Respir Dis 1991; 144: 1-2.
5. Wallace RJ, O'Brien R, Glassroth J, et al. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am Rev Respir Dis 1990; 142: 940-953.
6. Dautzenberg B, Saint-Marc T, Meyohas MC, et al. Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with the acquired immunodeficiency syndrome. Arch Intern Med 1993; 153: 368-372.
7. Perronne C, Gikas A, Truffot-Pernot C, Grosset J, Pocidalo J J, Vildé J L. Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages. Antimicrob Agents Chemother 1990; 34: 1508-1511.
8. Fernandes P B, Hardy D J, McDaniel D, Hanson C W, Swanson R N. In vivo and in vitro activities of clarithromycin against Mycobacterium avium. Antimicrob Agents Chemother 1989; 33: 1531-1534.
9. Dautzenberg B, Truffot C, Legris S, et al. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial. Am Rev Respir Dis 1991; 144: 564-569.
10. Doucet-Populaire F, Truffot-Pernot C, Grosset J, Jarlier V. Acquired resistance in Mycobacterium avium complex strains isolated from AIDS patients and beige mice during treatment with clarithromycin. J Antimicrob Chemother 1995; 36: 129-136.
11. Lounis N, Ji B, Truffot-Pernot C, Grosset J. Selection of clarithromycin-resistant Mycobacterium avium complex during combined therapy using the beige mouse model. Antimicrob Agents Chemother 1995; 39: 608-612.
12. Heifets L B, Lindholm-Levy P J, Constock R D. Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium. Am Rev Respir Dis 1992; 145: 856-858.
13. Wallace R J, Glassroth J, O'Brien R. A plea for clinical trials to resolve the issue of optimal therapy in the treatment of Mycobacterium avium infection. Am Rev Respir Dis 1991; 144; 3-4.
14. Tzukamura M. In-vitro antimycobacterial activity of minocy-cline. Tubercle 1980; 61: 37-38.
15. Cohen Y, Perronne C, Grosset J, Vildé J L, Pocidalo J J. Activities of WIN-57273, minocycline, clarithromycin, and 14-hydroxy-clarithromycin against Mycobacterium avium complex in human macrophages. Antimicrob Agents Chemother 1992; 36: 2104-2107.
16. Lazard T, Perronne C, Grosset J, Vildé J L, Pocidalo J J. Clarithromycin, minocycline, and rifabutin treatments before and after infection of C57BL/6 mice with Mycobacterium avium. Antimicrob Agents Chemother 1993; 37: 1690-1692.
17. Ji B, Perani E G, Grosset J H. Effectiveness of clarithromycin and minocycline alone and in combination against experimental Mycobacterium leprae infection in mice. Antimicrob Agents Chemother 1991; 35: 579-581.
18. Gangadharam P R J, Perumal V K, Jairan B T, et al. Activity of rifabutin alone or in combination with clofazimine or ethambutol or both against acute and chronic experimental Mycobacterium intracellulare infections. Am Rev Respir Dis 1987; 136: 329-333.
19. Saito H, Sato K. Activity of rifabutin alone and in combination with clofazimine, kanamycin and ethamburol against Myco-bacterium intracellulare infections in mice. Tubercle 1989; 70: 201-205.
20. Gangadharam P R J, Perumal V K, Popadati N R, Kesavalu L, Iseman M D. In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium complex infections in beige mice. Antimicrob Agents Chemother 1988; 32: 1400-1403.
21. Horsburgh C R. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med 1991; 324: 1332-1338.
22. Saint Marc T, Marneff E. Infections à Mycobacterium avium intracellulare. Traitement par la double association clarithro-mycine-clofazimine. 18 observations. Presse Méd 1993; 22: 1903-1907.
23. Ji B, Lounis N, Truffot-Pernot C, Grosset J. Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model. Antimicrob Agents Chemother 1994; 38: 2521-2529.
24. Heifets L, Mor N, Vanderkolk J. Mycobacterium avium strains resistant to clarithromycin and azithromycin. Antimicrob Agents Chemother 1993; 37: 2364-2370.
25. Ji B, Lounis N, Truffot-Pernot C, Grosset J. Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model. Antimicrob Agents Chemother 1994; 38: 2521-2529.
26. American National Tuberculosis Association. Diagnostic standards and classification of tuberculosis. New York: US National TB Assn 1961: pp 39-44.
27. Tuberculosis Chemotherapy Trial Committee, Medical Research Council. Long-term chemotherapy in the treatment of chronic pulmonary tuberculosis with cavitation. Tubercle 1962; 43: 201-267.
28. Wolinsky E. Mycobacterial diseases other than tuberculosis. Clin Infect Dis 1992; 15: 1-12.
29. Wallace R J, Brown B A, Griffith D E, et al. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am Respir Crit Care Med 1994; 149: 1335-1341.
30. Roussel G, Grosset J, Truffot C, Hazebroucq J, Legris S. Essai de traitement des mycobactérioses pulmonaires aviaires chez les patients VIH négatifs. Tubercle Lung Dis 1994; 75 (Suppl 1): 87.
31. Igual J, Roussel G, Truffot C, and the GETIM. Traitement des mycobactérioses aviaires pulmonaires chez les patients VIH né gatifs. Rev Mal Respir 1996; 112: R47.
32. Dautzenberg B, Piperno D, Diot P, Truffot-Pernot C, Chauvin J P, and the Clarithromycin Study Group of France. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Chest 1995; 107: 1035-1040.
33. Wallace R J, Brown B A, Griffith D E, Girard W M, Murphy D T. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care 1996; 153: 1766-1772.
34. Chaisson R E, Keiser P, Pierce M, et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS 1997; 11: 311-317.
35. May T, Brel F, Beuscart C, et al. Comparison of combination therapy regimens for treatment of human immunodeficiency virus-infected patients with disseminated bacteremia due to Mycobacterium avium. Clin Infect Dis 1997; 25: 621-629.
36. Diagnosis and treatment of disease caused by non tuberculous mycobacteria. Official statement of the American Thoracic Society, approved by the Board of Directors, March 1997. Am J Respir Crit Care Med 1997; 156: S1-S25.